Update on Current Role of Perioperative Chemotherapy in Upper Tract Urothelial Carcinoma
10.22465/kjuo.2018.16.3.89
- Author:
Byeong Jo JEON
1
;
Bum Sik TAE
;
Jae Young PARK
Author Information
1. Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. jaeyoungpark@korea.ac.kr
- Publication Type:Review
- Keywords:
Transitional cell carcinoma;
Chemotherapy;
Adjuvant;
Urinary tract
- MeSH:
Carcinoma, Transitional Cell;
Chemotherapy, Adjuvant;
Diagnosis;
Disease-Free Survival;
Drug Therapy;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Prevalence;
Renal Insufficiency;
Urinary Tract;
Urology
- From:Korean Journal of Urological Oncology
2018;16(3):89-96
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Upper tract urothelial carcinoma (UTUC) has a relatively low prevalence rate of about 1.8 per 100,000 people. According to the recent literature, the development of diagnostic techniques has gradually increased the prevalence and diagnosis rate. In the past, when UTUC was diagnosed, more than 60% of the patients were diagnosed as locally advanced or metastatic cancer. However, since 2010, approximately 70% of the patients have been diagnosed as operable stage. Although radical nephroureterectomy is known as the basis of treatment for UTUC, overall survival is poor in patients with lymph node invasion. Especially, the finding that a localized UTUC is associated with a high risk of cancer metastasis in approximately 50% of patients suggests that these patients may not have sufficient treatment through surgery alone. The European Association of Urology and the National Comprehensive Cancer Network guideline 2017 suggested that postoperative adjuvant chemotherapy may be considered in patients with advanced UTUC beyond pT2. Also, recent meta-analyses have reported that cisplatin-based adjuvant chemotherapy can be expected to have a synergistic effect of overall survival and disease-free survival. However, many patients with UTUC undergo postoperative renal failure, which may result in failure to perform cisplatin-based adjuvant chemotherapy with adequate dose. For this reason, several researchers have suggested that it is beneficial to apply neoadjuvant chemotherapy when the preoperative renal function is maintained to a certain extent. But, neoadjuvant chemotherapy has not been used by many clinicians because of the lack of studies and the rarity of the disease. We are currently discussing the outcomes and prospects of perioperative chemotherapy.
